The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
{{output}}
Introduction: Abnormal expression of epidermal growth factor receptor (EGFR) contributes to tumor development, especially in non-small cell lung cancer (NSCLC). Although multiple inhibitors have been developed to target diverse E... ...
